A federal jury in San Francisco, USA, ruled on the 20th local time that American entrepreneur Elon Musk intentionally depressed the stock price of Twitter (now renamed X) and "misled investors" during its acquisition in 2022, holding him liable for this. However, the jury dismissed the fraud allegation that Musk participated in "scheming" to mislead investors. The lawsuit was filed before Musk took over Twitter. The jury was asked to determine whether two tweets Musk posted in May 2022 and his remarks on a related podcast constituted "intentional fraud against Twitter shareholders." After nearly four days of deliberation, the nine-member jury ruled that Musk was liable for "misleading investors" by posting the aforementioned two tweets, but his remarks on the podcast did not constitute misleading, and he did not intentionally "scheme" to defraud investors.
This ruling represents a rare defeat for Musk, whose legal team stated they will appeal. Musk announced in April 2022 his intention to acquire Twitter for $44 billion and declared the termination of the acquisition agreement on July 8. Twitter sued Musk on July 12, accusing him of refusing to complete the acquisition as agreed and causing significant losses to the company. (Reuters)
Musk Suffers Rare Defeat: Found Liable for "Misleading Investors" During Twitter Acquisition
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
5
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
6
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
7
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
8
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
9
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
-
10
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
Markets Today
Recommended Reading







